Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/jco.1991.9.9.1668PMID 1831495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.

  1990cited by this paper
• Adjuvant chemotherapy in head and neck cancer.

  1990cited by this paper
• Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.

  1989cited by this paper
• Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4′‐epi‐doxorubicin in the treatment of advanced ovarian cancer

  1988cited by this paper
• A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.

  1987cited by this paper
• Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews.

  1987cited by this paper
• Publication bias: the case for an international registry of clinical trials.

  1986cited by this paper
• A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.

  1986cited by this paper
• High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia.

  1982cited by this paper

• Minimization in randomized clinical trials

  2023cites this paper
• The methodological quality of individual participant data meta-analysis on intervention effects: systematic review

  2021cites this paper
• Concordance index: Surrogacy of progression-free survival for overall survival.

  2021cites this paper
• Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

  2018cites this paper
• Clinical Trials in Ovarian Cancer

  2017cites this paper
• How individual participant data meta-analyses have influenced trial design, conduct, and analysis

  2015cites this paper
• Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy -a retrospective evaluation. .

  2014cites this paper
• Paclitaxel-exposed ovarian cancer cells induce cancer‑specific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression.

  2014cites this paper
• A comparison of the generation of free radicals in saliva of active and passive smokers.

  2014cites this paper
• Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

  2013cites this paper
• Pegylated liposomal doxorubicin for platinum-resistant or refractory Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience.

  2013cites this paper
• Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

  2013cites this paper
• Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.

  2013cites this paper
• Pharmaceutical Management of Ovarian Cancer

  2012cites this paper
• A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer.

  2012cites this paper
• Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.

  2012cites this paper
• First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.

  2012cites this paper
• Pursuit of Optimum Outcomes in Ovarian Cancer

  2012cites this paper
• A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials.

  2012cites this paper
• Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.

  2012cites this paper
• Thérapeutiques du cancer de l’ovaire

  2011cites this paper
• Ovarialkarzinom: alte Probleme und neue Lösungsansätze

  2011cites this paper
• Chemotherapy in epithelial ovarian cancer.

  2011cites this paper
• Epithelial ovarian cancer.

  2011cites this paper
• First-line treatment of advanced ovarian cancer: current research and perspectives

  2010cites this paper
• Protocol Development for Ovarian Cancer Treatment in Kenya: A Brief Report

  2010cites this paper
• The impact of autologous bone marrow transplantation on hematopoietic recovery after high-dose cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with gynecological malignancies.

  2010cites this paper
• Achievements and unmet needs in the management of advanced ovarian cancer.

  2010cites this paper
• Scope of nanotechnology in ovarian cancer therapeutics

  2010cites this paper
• The Effective Sample Size and an Alternative Small-Sample Degrees-of-Freedom Method

  2009cites this paper
• Role of meta-analyses and of large randomized trials in the study of cancer treatments.

  2009cites this paper
• A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis

  2008cites this paper
• Progression-free versus overall survival and adequate powering in randomised studies.

  2008cites this paper
• Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

  2008cites this paper
• Clinical Outcome and Prognostic Factors in Borderline Ovarian Tumors and Invasive Ovarian Carcinomas in Western Sweden

  2008cites this paper
• Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial

  2008cites this paper
• Progress in gynecologic cancer research: the Gynecologic Oncology Group experience.

  2008cites this paper
• Ovarian cancer: front-line standard treatment in 2008.

  2008cites this paper
• Expression of Organic Cation Transporter SLC22A16 in Human Epithelial Ovarian Cancer: A Possible Role of the Adriamycin Importer

  2007cites this paper
• Intraperitoneal Chemotherapy of Ovarian Cancer

  2007cites this paper
• A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer.

  2007cites this paper
• Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.

  2007cites this paper
• Facteurs pronostiques et chimiothérapie de première ligne des adénocarcinomes ovariens

  2006cites this paper
• Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study

  2006cites this paper
• Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer.

  2006cites this paper
• Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.

  2006cites this paper
• Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.

  2006cites this paper
• Les résultats de la chimiothérapie initiale des formes avancées des cancers épithéliaux de l’ovaire

  2006cites this paper
• Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

  2006cites this paper
• Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.

  2006cites this paper
• Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau

  2006cites this paper
• Phase I Study of Pegylated Liposomal Doxorubicin in Combination With Ifosfamide in Pretreated Ovarian Cancer Patients

  2006cites this paper
• Ovarian cancer.

  2006cites this paper
• Management Strategies for Partially Platinum-Sensitive Ovarian Cancer

  2006cites this paper
• Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation

  2006cites this paper
• Current management of ovarian carcinoma

  2005cites this paper
• Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.

  2005cites this paper
• Epithelial ovarian cancer: a review of current management.

  2005cites this paper
• Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer

  2005cites this paper
• Emerging drugs for ovarian cancer

  2005cites this paper
• Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma.

  2005cites this paper
• Clinical trials in ovarian carcinoma: study methodology.

  2005cites this paper
• Role of Pegylated Liposomal Doxorubicin (PLD) in Epithelial Ovarian Cancer

  2004cites this paper
• A Phase II Study of Liposomal Doxorubicin in Recurrent Epithelial Ovarian Carcinoma

  2004cites this paper
• The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.

  2004cites this paper
• Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.

  2004cites this paper
• Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.

  2004cites this paper
• Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trial.

  2004cites this paper
• Liposomal anthracycline treatment for ovarian cancer.

  2004cites this paper
• [Advances in the treatment of ovarian carcinoma].

  2004cites this paper
• Remaining controversies in the upfront management of advanced ovarian cancer

  2004cites this paper
• Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).

  2003cites this paper
• Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer.

  2003cites this paper
• Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer

  2003cites this paper
• An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer.

  2003cites this paper
• Using t he E xpected S urvival t o E xplain D ifferences Between t he R esults o f R andomized T rials: A C ase i n A dvanced O varian C ancer

  2003cites this paper
• Systemic treatment policies in ovarian cancer: the next 10 years

  2003cites this paper
• Oral Etoposide (VP16) in Platinum-Resistant Epithelial Ovarian Cancer (EOC)

  2003cites this paper
• Optimizing primary chemotherapy in ovarian cancer.

  2003cites this paper
• Progress in ovarian cancer

  2003cites this paper
• Paclitaxel nicht mehr erste Wahl beim Ovarialkarzinom?

  2003cites this paper
• The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients

  2003cites this paper
• Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens.

  2003cites this paper
• State-of-the-Art First-Line Treatment of Ovarian Cancer

  2003cites this paper
• Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer

  2003cites this paper
• Targeted therapy for epithelial ovarian cancer: Current status and future prospects

  2003cites this paper
• First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin

  2003cites this paper
• Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I–II study

  2003cites this paper
• Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma.

  2003cites this paper
• HPMA copolymer delivery of chemotherapy and photodynamic therapy in ovarian cancer.

  2003cites this paper
• First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients.

  2003cites this paper
• Peritoneal Carcinoma in a Male Patient

  2003cites this paper
• Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

  2002cites this paper
• A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer

  2002cites this paper
• Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.

  2002cites this paper
• Polychemotherapy in Ovarian Cancer in Patients over Seventy Years of Age

  2002cites this paper
• Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study.

  2002cites this paper
• Anthracyclines in the treatment of gynecologic malignancies.

  2002cites this paper
• Epithelial ovarian cancer: second and third line chemotherapy (review).

  2002cites this paper
• Advances in the treatment of gynecologic malignancies. Part 2: Cancers of the uterine corpus and ovary.

  2002cites this paper